In this HCPLive Peers & Perspectives series, panelists examine the evolving psoriasis treatment landscape, focusing on the clinical utility and safety profile of selective TYK2 inhibitors as a potent oral alternative to biologics. The series provides expert guidance on shared decision-making, addressing patient-reported outcomes, and managing systemic comorbidities to achieve optimal long-term health and skin clearance.
This discussion will examine current and emerging colorectal cancer screening strategies and explore how these approaches can be practically implemented in real-world clinical practice. It will focus on how evidence, patient factors, and operational considerations come together to shape effective colorectal cancer testing protocols.
·Examine the evolving standard of care in wet AMD, DME, and RVO, with a focus on how next-generation anti-VEGF agents are enhancing efficacy and durability.
·Discuss clinical strategies that leverage the flexibility of newer anti-VEGF treatments to individualize care, reduce treatment burden, and optimize visual outcomes in diverse patient populations.
Panelists discussion will focus on the evolving treatment landscape in plaque psoriasis with novel therapeutic approaches, such as TYK2 inhibition. Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.
Panelists discuss how deucravacitinib and apremilast compare in efficacy, safety, and patient-centered outcomes, emphasizing individualized psoriasis management through convenient and effective oral therapy options.
Optimizing Therapeutic Strategies in Inflammatory Bowel Disease is a feature program in the HCP Live® Peers & Perspectives series, offering an in-depth discussion on the evolving standards of care in IBD. This expert exchange examines how new definitions of remission, early treatment interventions, and advanced therapeutic options are reshaping patient management. The program explores emerging clinical evidence, compares traditional and novel endpoints, and highlights how real-world application of evolving therapies can enhance disease control, support personalized treatment strategies, and ultimately improve long-term outcomes for individuals living with IBD.
Panelists discuss how emerging oral therapies like TYK2 inhibitors, next-generation PDE4 inhibitors, and the novel oral IL-23 receptor blocker icotrokinra are achieving unprecedented efficacy levels in psoriasis treatment, with some oral agents now demonstrating complete skin clearance rates and superior performance in high-impact areas like scalp and genital psoriasis. The panelists emphasize the importance of shared decision-making, early intervention, and addressing treatment gaps through patient-centered care approaches.
Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discuss how Janus kinase (JAK) inhibitors are revolutionizing atopic dermatitis treatment by providing faster, deeper, and more durable responses than biologics, particularly for patients who haven’t achieved optimal treatment targets of simultaneous skin clearance and itch relief as defined by the AHEAD recommendations.
Panelists discuss how early diagnosis of Alzheimer disease and the proactive involvement of frontline clinicians are essential to timely identification and implementation of best practices for optimal patient care.
Gus Alva, MD; and Hara Oyedeji, MSN, MSEd, PMHNP-BC, APRN discuss how schizophrenia encompasses 3 distinct symptom domains beyond merely hallucinations, the limitations of current dopamine-blocking treatments, and the promising emergence of xanomeline trospium chloride as a novel muscarinic agonist that offers hope for more comprehensive treatment of this complex neuropsychiatric condition affecting millions worldwide.
Panelists discuss how familial chylomicronemia syndrome (FCS) is diagnosed and managed, emphasizing the role of early intervention in preventing severe complications and exploring current and emerging RNA interference–based therapies, such as APOC3 and ANGPTL3 inhibitors, which offer new avenues for effective triglyceride control and potential improvements in patient outcomes.
Silvio Danese, MD, PhD, Bruce Sands, MD, and Jean-Frederic Colombel, MD, share their insights on the current landscape of ulcerative colitis treatment, focusing on the role of biologic therapies, the emerging concept of dual advanced therapy, and various monitoring methods used to assess treatment progress, ensuring optimal patient outcomes and timely adjustment of therapeutic strategies when needed.
The treatment landscape of plaque psoriasis has expanded over the years. Advanced practice providers are taking a deep dive into the oral systemic space and review recently published long term data on TYK2 inhibitors.
Advanced practice providers in dermatology take a deep dive in the latest developments of systemic and biologic therapies in atopic dermatitis (AD). The experts discuss the new and emerging agents as well as clinical trial data. They also review which patient makes a good candidate for systemic therapy and focus on how advanced practice providers play a critical role in optimizing treatment in AD.
Dr Andrew Cutler and Dr Greg Mattingly talk about medications with newer mechanisms of action, in particular glutamatergic agents, for the treatment of depression. They also discuss the impact of unresolved depression symptoms, especially anhedonia, on patients’ quality of life and function.
Experts in nephrology take a deep dive into the latest developments in immune-modulating therapies in IgA (immunoglobulin A) nephropathy. They discuss the different mechanisms of actions and the most recent clinical trial data, as well as take a look into the future on how to incorporate novel therapies into clinical practice once they become available.
Retina specialists discuss therapies that promise to reduce the treatment burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) through extended durability. They also highlight the latest clinical data on the efficacy and safety of these therapies.
Expert dermatologists discuss the impact of plaque psoriasis on patient quality of life and take a deep dive into inhibitors of interleukin-23 (IL-23), reviewing clinical trial data and real-world data, and providing an overview of how IL-23 inhibitors contribute to a rising standard for psoriasis outcomes.
Expert retina specialists discuss the biosimilar approval process, review the currently available anti-VEGF biosimilars, and share practical considerations for adopting biosimilars for the treatment of retinal diseases.
An expert physician assistant and a nurse practitioner discuss new treatments for plaque psoriasis. They focus on treatment safety, efficacy, and their role in the management of patients with plaque psoriasis.
Experts in hepatology discuss hepatic encephalopathy (HE), factors that put patients with liver disease at higher risk of developing HE, and the importance of early recognition and treatment. They share thoughts on using a holistic approach to managing patients with liver disease.
In this program, Arun Jesudian, MD, and James Williams, MS, DO, FACEP, highlight characteristics that put hospitalized patients at higher risk of developing hepatic encephalopathy (HE). These experts share suggestions for monitoring hospitalized patients and how proper discharge planning and transition-of-care can reduce the risk of rehospitalization for HE.
Linda Stein Gold, MD, and Bruce Strober, MD, PhD discuss the mechanisms, data, and impact of tyrosine kinase 2 inhibitors.
Experts discuss the importance of early screening for type 1 diabetes, screening guidelines, and emerging treatments that can delay the onset of type 1 diabetes.
An expert physician assistant and a nurse practitioner discuss the role of long-term and real-world data regarding the safety and efficacy of IL-23 inhibitors in the management of patients with plaque psoriasis.
Expert healthcare practitioners discuss insulin delivery methods, focusing on inhaled insulin, its pharmacological properties, and data on glycemic control in type 1 diabetes. The panelists also talk about the use of inhaled insulin in type 2 diabetes and emerging data on oral insulin.
Advanced practice practitioners discuss the co-occurrence of sleep disorders with other health conditions, patient awareness, and the importance of screening for sleep disorders. They also discuss the treatment landscape of insomnia and the use of dual orexin receptor antagonists in the management of insomnia.
Expert dermatologist and physician assistant review updates in the management of Plaque Psoriasis.
Updated recommendations to managing type 2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists and preventing cardiovascular events.
